Comparison of dopamine D2 receptor occupancy profiles between risperidone ism versus oral risperidone and monthly paliperidone palmitate based on population pharmacokinetic modelling and simulations

Risperidone-ISM® achieves threshold D2RO on the first injection day and predicts higher median time above 65% D2RO than high OR doses in real clinical practice. A much faster onset of action and better D2RO coverage during the dosing interval was predicted for Risperidone-ISM® versus PP1M. Simulations suggest that Risperidone-ISM® compares favorably with high doses of OR and PP1M, making it an effective therapeutic strategy for rapid and sustained symptom reduction.